Article
Hematology
Huimin Feng, Yue Fu, Zelong Cui, Minran Zhou, Lu Zhang, Zhenxing Gao, Sai Ma, Chunyan Chen
Summary: This study shows that PHF8 is significantly increased in CML patients and inhibits cell differentiation while promoting cell proliferation. Targeting PHF8, which directly regulates BCR::ABL1 expression, may be a useful therapeutic approach for CML.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Michael Lauseker, Ruediger Hehlmann, Andreas Hochhaus, Susanne Saussele
Summary: The therapy after failing response milestones in CML is controversial, and there is a lack of information on the long-term survival of these patients. A study on patients from CML-study IV showed that the survival rate of patients who failed the failure milestones was approximately 10% lower than those who reached the milestones, suggesting a need for revising these milestones.
Review
Medicine, General & Internal
Jorge Cortes, Carolina Pavlovsky, Susanne Saussele
Summary: Tyrosine-kinase inhibitors have significantly altered the natural course of chronic myeloid leukaemia, allowing some patients to approach a near-normal life expectancy. Successful treatment requires understanding the patient's treatment goals, monitoring optimal response hallmarks, timely interventions, recognition of adverse events, and management of comorbidities.
Article
Oncology
Richard E. Clark, Ammar A. Basabrain, Gemma M. Austin, Alison K. Holcroft, Sandra Loaiza, Jane F. Apperley, Christopher Law, Laura Scott, Alexandra D. Parry, Laura Bonnett, Claire M. Lucas
Summary: The high levels of diagnostic CIP2A are associated with disease progression and treatment failure in chronic myeloid leukemia patients, making it a potentially useful diagnostic tool for treatment planning.
Article
Hematology
Hagop M. Kantarjian, Mary Alma Welch, Elias Jabbour
Summary: This article analyzes the risks and benefits of established treatment practices for BCR::ABL1 tyrosine kinase inhibitors (TKIs) in chronic myeloid leukaemia and suggests that lower doses of TKIs can achieve similar treatment efficacy with less toxicity, better treatment compliance, and reduced cost of care. It also highlights that changing TKIs might not be necessary for patients who do not have an early molecular response, particularly for second-generation TKIs. The availability of generic TKIs would provide an effective, safe, and affordable therapy for the majority of chronic myeloid leukaemia patients. Any TKI costing more than $30,000-40,000 per year should be evaluated in relation to alternative modalities.
LANCET HAEMATOLOGY
(2023)
Article
Hematology
Dennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G. Atenafu, Igor Novitzky Basso, Donna Forrest, Isabelle Bence-Bruckler, Lynn Savoie, Lambert Busque, Mary-Margaret Keating, Robert Delage, Anargyros Xenocostas, Elena Liew, Kristjan Paulson, Tracy Stockley, Pierre Laneuville, Jeffrey H. Lipton, Suzanne Kamel-Reid, Brian Leber
Summary: The study found that monthly assessment of doubling time can help identify the risk of molecular recurrence in patients with chronic myeloid leukemia after discontinuation of imatinib, thereby distinguishing between high-risk and low-risk patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xiuyan Zhang, Yu Wang, Jinchang Lu, Lun Xiao, Hui Chen, Quanxue Li, Yuan-Yuan Li, Peng Xu, Changgeng Ruan, Haixia Zhou, Yun Zhao
Summary: This study identified a novel ZFX/WNT3 axis that modulates the growth and drug response of CML stem/progenitor cells.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2023)
Article
Oncology
Joseph M. M. Unger, Michael LeBlanc, Suzanne George, Norman Wolmark, Walter J. J. Curran Jr, Peter J. J. O'Dwyer, Mitchell D. D. Schnall, Robert S. S. Mannel, Sumithra J. J. Mandrekar, Robert J. J. Gray, Fengmin Zhao, Mariama Bah, Riha Vaidya, Charles D. D. Blanke
Summary: The National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups in the United States have conducted publicly funded oncology research for 50 years, but the combined impact of all adult network group trials has never been systematically examined.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Yotaro Ochi, Kenichi Yoshida, Ying-Jung Huang, Ming-Chung Kuo, Yasuhito Nannya, Ko Sasaki, Kinuko Mitani, Noriko Hosoya, Nobuhiro Hiramoto, Takayuki Ishikawa, Susan Branford, Naranie Shanmuganathan, Kazuma Ohyashiki, Naoto Takahashi, Tomoiku Takaku, Shun Tsuchiya, Nobuhiro Kanemura, Nobuhiko Nakamura, Yasunori Ueda, Satoshi Yoshihara, Rabindranath Bera, Yusuke Shiozawa, Lanying Zhao, June Takeda, Yosaku Watatani, Rurika Okuda, Hideki Makishima, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Masashi Sanada, Akifumi Takaori-Kondo, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih
Summary: In chronic myeloid leukaemia (CML), the drivers of blast crisis and resistance to tyrosine kinase inhibitors are not fully characterised. Analysis of a cohort of CML samples using genomic technologies reveals that at least one driver alteration is associated with progression and worse prognosis. Genetic abnormalities can help predict clinical outcomes and guide clinical decisions in CML.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Sarah Allegra, Emma Dondi, Francesco Chiara, Silvia De Francia
Summary: This study examined the influence of age and sex on the levels of tyrosine kinase inhibitors in plasma and cerebrospinal fluid of patients with chronic myeloid leukaemia. Results showed an inverse correlation between age and imatinib plasma concentration, and lower dasatinib concentrations in plasma compared to cerebrospinal fluid, especially in paediatric patients. Therapeutic drug monitoring, along with tyrosine kinase inhibitors, is supported for the treatment of chronic myeloid leukaemia. Refinement of the classification of tyrosine kinase inhibitor therapeutic drug monitoring should consider factors like sex and age.
Article
Oncology
Ismail Siti Mariam, Ramli Norhidayah, Abu Bakar Zulaikha, Mohd Yunus Nazihah, Hassan Rosline, Ghazali Anis Kausar, Sulong Sarina, Husin Azlan, Ravindran Ankathil
Summary: This study reports the type, frequency, and prognostic impact of additional chromosome abnormalities (ACAs) in Malaysian chronic myeloid leukemia (CML) patients undergoing treatment with tyrosine kinase inhibitors (TKIs). The patients with ACAs were stratified into different groups, and it was found that the prognostic outcomes varied significantly among these groups. This study suggests that stratification based on individual ACAs can help predict prognosis and guide treatment decisions for CML patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Michele Baccarani, Francesca Bonifazi, Simona Soverini, Fausto Castagnetti, Gabriele Gugliotta, Wael Saber, Noel Estrada-Merly, Gianantonio Rosti, Robert Peter Gale
Summary: This commentary discusses important questions regarding the treatment of chronic myeloid leukaemia (CML) and compares the benefits and risks of tyrosine kinase-inhibitor (TKI) therapy and transplantation. The authors suggest that a small proportion of patients with CML can achieve sustained therapy-free remission with TKI therapy, while others may need lifelong treatment. Transplants offer higher rates of leukaemia-free survival, but are associated with adverse events and complications. The authors propose that transplantation should be considered more often as a treatment option for CML patients unlikely to achieve therapy-free remission with TKI therapy.
Article
Multidisciplinary Sciences
Stella Pearson, Anthony D. Whetton, Andrew Pierce
Summary: Despite advances in precision medicine targeted therapies for cancer, the development of curative treatments remains challenging due to drug resistance in cancer stem cells. Chronic myeloid leukemia is a model for studying cancer stem cells and although targeted therapies have been developed, drug resistance remains a problem. New treatment strategies are needed to target other components within leukemia stem cells, either alone or in combination with existing therapies.
Article
Medicine, Research & Experimental
Kinjal D. Patel, Maitri De, Disha D. Jethva, Bharati S. Rathod, Prabhudas S. Patel
Summary: This study investigated the predictive value of sialylation changes in assessing imatinib mesylate (IM) resistance in chronic myeloid leukemia (CML) cases. The results showed that alterations in TSA, ST3GAL1, and ST3GAL2 levels were associated with IM resistance, providing clinical relevance in treatment monitoring and IM resistance treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Lisa Repsold, Roger Pool, Mohammed Karodia, Gregory Tintinger, Piet Becker, Anna Margaretha Joubert
Summary: This study found that platelet counts in CML patients were elevated upon diagnosis and significantly decreased after 6 months of treatment. Platelet activation and apoptosis increased after 6 months of treatment compared to levels at diagnosis. Abnormalities in platelet functioning in CML patients may be due to clonal proliferation of hematopoietic cells and inhibition of platelet tyrosine kinase's and platelet-derived growth factor.
CELL BIOCHEMISTRY AND FUNCTION
(2021)
Article
Rheumatology
Fabricio Souza Neves, Thais Helena Otto da Silva, Gislaine Paviani, Adriana Fontes Zimmermann, Glaucio Ricardo Werner de Castro, Ivanio Alves Pereira
CLINICAL RHEUMATOLOGY
(2010)
Article
Immunology
Kenia Rodrigues de Andrade, Glaucio Ricardo Werner de Castro, Geison Vicente, Julia Salvan da Rosa, Marina Nader, Ivanio Alves Pereira, Tania Silvia Froede
INTERNATIONAL IMMUNOPHARMACOLOGY
(2014)
Article
Immunology
Glaucio Ricardo Werner de Castro, Ziliani Buss, Julia Salvan Da Rosa, Tania Silvia Froede
INTERNATIONAL IMMUNOPHARMACOLOGY
(2014)
Article
Rheumatology
Fernanda Vicente da Costa, Sonia Cristina de Magalhaes Souza Fialho, Adriana F. Zimmermann, Fabricio S. Neves, Glaucio Ricardo Werner de Castro, Ivanio Alves Pereira
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2010)
Article
Rheumatology
Willian Cruz, Sonia Fialho, Edelton Morato, Glaucio Castro, Adriana Zimmermann, Giovana Ribeiro, Fabricio Neves, Ivanio Pereira
Article
Endocrinology & Metabolism
G. R. Werner de Castro, F. S. Neves, S. C. de Magalhaes Souza Fialho, I. A. Pereira, G. Ribeiro, A. F. Zimmermann
OSTEOPOROSIS INTERNATIONAL
(2010)
Article
Rheumatology
Glaucio Ricardo Werner de Castro, Glaucia Itamaro Heiden, Adriana Fontes Zimmermann, Edelton Flavio Morato, Fabricio Souza Neves, Maria Amazile Toscano, Sonia Cristina de Magalhaes Souza Fialho, Ivanio Alves Pereira
RHEUMATOLOGY INTERNATIONAL
(2012)
Article
Rheumatology
Glaucio Ricardo Werner de Castro, Fabricio Souza Neves, Ivanio Alves Pereira, Sonia Cristina Magalhaes Souza Fialho, Giovana Ribeiro, Adriana Fontes Zimmermann
RHEUMATOLOGY INTERNATIONAL
(2012)
Article
Rheumatology
Igor Kunze Rodrigues, Michele Andrigueti, Ione Dilma de Oliveira Gil, Leonardo de Lucca Schiavon, Kenia Rodrigues de Andrade, Ivanio Alves Pereira, Glaucio Ricardo Werner de Castro, Adriana Fontes Zimmermann, Luciano Nascimento Saporiti, Maria Luiza Bazzo, Fabricio Souza Neves
RHEUMATOLOGY INTERNATIONAL
(2015)
Article
Rheumatology
Renato Leandro Mattar Valente, Jamil Mattar Valente, Glaucio Ricardo Werner de Castro, Adriana Fontes Zimmermann, Sonia Cristina de Magalhaes Souza Fialho, Ivelnio Alves Pereira
REVISTA BRASILEIRA DE REUMATOLOGIA
(2013)
Article
Rheumatology
Sonia Cristina de Magalhaes Souza Fialho, Samuel Bergamaschi, Fabricio Souza Neves, Adriana Fontes Zimmermann, Glaucio Ricardo Werner de Castro, Ivanio Alves Pereira
REVISTA BRASILEIRA DE REUMATOLOGIA
(2012)
Article
Rheumatology
Flavia Yuri Shiguematsu, Elaine Cristina Caon de Souza, Adriana Fontes Zimmermann, Glaucio Ricardo Werner Castro, Ivanio Alves Pereira, Fabricio Souza Neves
REVISTA BRASILEIRA DE REUMATOLOGIA
(2012)
Article
Rheumatology
Leticia Stahelin, Sonia Cristina de Magalhaes Souza Fialho, Fabricio Souza Neves, Larissa Junckes, Glaucio Ricardo Werner de Castro, Ivanio Alves Pereira
REVISTA BRASILEIRA DE REUMATOLOGIA
(2012)
Article
Rheumatology
Sonia Cristina de Magalhaes Souza Fialho, Glaucio Ricardo Werner de Castro, Adriana Fontes Zimmermann, Giovana Gomes Ribeiro, Fabricio Souza Neves, Ivanio Alves Pereira, Guilherme Loureiro Fialho
REVISTA BRASILEIRA DE REUMATOLOGIA
(2011)
Review
Rheumatology
Maria Chiara Maccarone, Daniele Coraci, Gianluca Regazzo, Nicola Sarandria, Anna Scanu, Stefano Masiero
Summary: Long COVID syndrome refers to the new, returning, or persistent symptoms after the initial SARS-CoV-2 infection. Musculoskeletal symptoms have a significant impact on the quality of life in many patients. A literature review was conducted to explore the evolution of musculoskeletal symptoms in Long COVID syndrome. The findings highlight the need for interdisciplinary management and timely rehabilitative interventions.
Review
Rheumatology
Alexis Mathian, Renaud Felten, Marta E. Alarcon-Riquelme, Antony Psarras, Philippe Mertz, Francois Chasset, Edward M. Vital, Laurent Arnaud
Summary: Improved understanding of the molecular basis of innate immunity has led to the recognition of type I interferons (IFNs) as key mediators in the development of immunemediated inflammatory diseases (IMIDs). Pharmacological targeting of IFNs and their downstream signaling pathways, such as JAK1 and Tyk2, holds promise for the treatment of IMIDs.
Review
Rheumatology
Marie Robert, Marc Scherlinger
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation and organ injury, involving the active role of platelets in the pathogenesis and disease progression. Platelets in SLE patients show intrinsic differences and can perpetuate inflammation by interacting with immune cells, thereby participating in organ damage and heightened cardiovascular mortality.
Review
Rheumatology
Jean Sibilia, Fabrice Berna, Jean-Gerard Bloch, Marc Scherlinger
Summary: Mind-body practices, such as mindfulness meditation, yoga, and Tai Chi, show promise in improving patient-reported outcomes in chronic rheumatic diseases, but their impact on inflammation and structural progression remains unclear.
Review
Rheumatology
Anne Tournadre, Marine Beauger
Summary: Obesity alters the characteristics of adipose tissue, leading to chronic low-grade inflammation, increased risk of chronic inflammatory diseases, and impact on treatment efficacy. Dietary and weight adjustments have a positive effect on improving inflammatory rheumatic diseases.
Article
Rheumatology
Romain Fore, Eric Liozon, Stephanie Dumonteil, Thomas Sene, Emmanuel Heron, Valentin Lacombe, Mathilde Leclercq, Julie Magnant, Clement Beuvon, Alexis Regent, Donatienne de Mornac, Maxime Samson, Perrine Smets, Jean-Francois Alexandra, Brigitte Granel, Pierre-Yves Robert, Muhammad Faiz Curumthaullee, Simon Parreau, Sylvain Palat, Holy Bezanahary, Kim Heang Ly, Anne-Laure Fauchais, Guillaume Gondran
Summary: This study aimed to evaluate whether the use of intravenous pulse of methylprednisolone reduces the risk of bilateral visual ischemia in patients with giant cell arteritis. The results showed no significant difference in the incidence of bilateral visual ischemia between the group receiving intravenous pulse of methylprednisolone and the group receiving direct prednisone.
Review
Rheumatology
Florent Eymard, Judith Aron-Wisnewsky
Summary: Obesity is a major modifiable risk factor for osteoarthritis (OA) and is associated with poorer outcomes in terms of pain, functional limitations, and response to treatments. Bariatric surgery (BS) can significantly reduce symptoms and improve function in patients with symptomatic knee OA, but its impact on long-term complications of arthroplasties appears to be disappointing. Overall, BS shows promise in reducing OA symptoms and potentially slowing disease progression.
Review
Rheumatology
Georges Marouna, Christina Fissouna, Marina Villaverde, Jean-Marc Brondelloa, Yves-Marie Pers
Summary: Recent discoveries have shown that the presence of senescent cells in osteoarticular tissues plays a crucial role in the development of osteoarthritis (OA). However, the senescence-regulatory factors associated with OA still need to be identified. Additionally, there is a lack of diagnostic and prognostic biomarkers currently used in clinics to evaluate OA patients. In the future, detecting senescence-regulatory biomarkers in patient fluids, along with imaging and clinical examination, could become a promising method for diagnosing, monitoring, assessing progression, and predicting prognosis in OA patients.
Article
Rheumatology
Patrick Yousif, Vicky Nahra, Muhammad A. Khan, Marina Magrey
Summary: Axial psoriatic arthritis (axPsA) has unique clinical and radiographic features compared to axial spondyloarthritis (axSpA). IL-23 inhibitors may be effective in treating axPsA, but further clinical trials are needed. Developing classification criteria and assessment tools for axPsA is also necessary.
Review
Rheumatology
Baptiste Gerard, Florian Bailly, Anne-Priscille Trouvin
Summary: This review aims to critically evaluate the effectiveness and safety of pharmacological treatments for chronic pain in rheumatic diseases, providing guidance for clinicians in selecting appropriate treatment options. The recommended pharmacological treatments vary depending on the specific rheumatic disease.
